A Phase 2, Randomized, Open-Label, 12-Week Study toAssess the Pharmacodynamics, Safety, Tolerability, andPharmacokinetics of Multiple Doses of GLM101Administered Intravenously to Adult Participants withPMM2-CDG

Project: Research project

Project Details

Description

A Phase 2, Randomized, Open-Label, 12-Week Study to Assess the Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of GLM101 Administered Intravenously to Adult Participants with PMM2-CDG
StatusActive
Effective start/end date12/14/22 → 8/30/27

Funding

  • GLYCOMINE, INC

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.
View full fingerprint